Viktor Frauenklinik Und Poliklinik Magdolen - Gynecology

Author Information

Viktor Magdolen is affiliated with the Clinical Research Unit, Department of Obstetrics and Gynecology, Technical University of Munich, located at Ismaninger Str. 22, D-81675, Munich, Germany. His research primarily focuses on the field of gynecology, with a particular interest in cancer studies, including ovarian and breast cancer. His work involves investigating various biomarkers and molecular mechanisms that influence cancer progression and treatment outcomes.

Research Contributions

Viktor Magdolen has made significant contributions to the understanding of gynecological cancers. His research includes studies on the role of chemokines, kallikrein-related peptidases, and microRNAs in cancer biology and treatment. Some of his notable works include exploring the inhibitory effects of CXCL9 on tumor growth in ovarian cancer, the prognostic value of kallikrein-related peptidases in triple-negative breast cancer, and the enhancement of trastuzumab efficacy by the chemokine CX3CL1. His research has implications for improving diagnostic and therapeutic strategies in cancer treatment.

Aliases

Viktor Magdolen is also known by the following aliases: V Magdolen, V. Magdolen, and Viktor Frauenklinik Und Poliklinik Magdolen.

Publication and Citation Metrics

Metric	Value
H-index	47
Citation Count	6896
Paper Count	264

Publications:

CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer.

DOI: 10.1038/s41416-022-01763-0

Year: 2022

Kallikrein-related peptidases in triple negative breast cancer: prognostic value of quantitatively assessed KLK8, KLK10 and KLK11 mRNA expression

DOI: 10.21203/RS.3.RS-365110/V1

Year: 2021

The prognostic and diagnostic potential of kallikrein-related peptidases in ovarian cancer

DOI: 10.1080/14737159.2021.1924680

Year: 2021

Rab31-dependent regulation of transforming growth factor ß expression in breast cancer cells

DOI: 10.1186/s10020-021-00419-8

Year: 2021

Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1

DOI: 10.1038/s41589-021-00783-w

Year: 2021

The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer In Vitro and In Vivo

DOI: 10.1158/2326-6066.CIR-20-0327

Year: 2021

Kallikrein-Related Peptidase 6 Is Associated with the Tumour Microenvironment of Pancreatic Ductal Adenocarcinoma

DOI: 10.3390/cancers13163969

Year: 2021

Epigenetic modulators combination with chemotherapy in breast cancer cells

DOI: 10.1002/cbf.3626

Year: 2021

tRNAGlyGCC-Derived Internal Fragment (i-tRF-GlyGCC) in Ovarian Cancer Treatment Outcome and Progression

DOI: 10.3390/cancers14010024

Year: 2021

Elevated levels of both microRNA 378 (miR-378) and kallikrein-related peptidase 4 (KLK4) mRNA are associated with an unfavorable prognosis in triple-negative breast cancer.

DOI:

Year: 2021

What are the Legal Aspects?

Why is limiting salt intake important in gynecology?

What Are Self Exams?

Can Antipsychotics Affect Fertility?

Can I Do Anything to Prevent Abnormal Pap Smear Results?

What is the Normal Menstrual Cycle Length?

What are the Challenges with Insurance Verification?

What Causes Vertex Presentation?

How Can Partners Be Involved in Cancer Screenings and Treatments?

Why Does Postpartum Swelling Occur?

Partnered Content Networks

Relevant Topics